# Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Source: https://onco.cc/trials/nct05009836/  
OnCo record `nct05009836` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Savolitinib in non-small-cell lung cancer and small-cell lung cancer, run by Hutchmed, active and no longer recruiting.

## Summary

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT05009836 by Hutchmed, with 412 participants planned, started 2021-09-06 and due to reach its primary completion in 2028-05-30. Interventions recorded: Savolitinib, Placebo. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05009836
- Phase: 3
- Setting: A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
- Sponsor: Hutchmed
- Enrolled: 412

## Sources

- ClinicalTrials.gov NCT05009836: https://clinicaltrials.gov/study/NCT05009836

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Savolitinib](https://onco.cc/drugs/savolitinib/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)

---
JSON: https://onco.cc/api/v1/entities/nct05009836.json